Intrinsic value of Biocept - BIOC

Previous Close

$6.22

  Intrinsic Value

$0.01

stock screener

  Rating & Target

str. sell

-100%

Previous close

$6.22

 
Intrinsic value

$0.01

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of BIOC stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  200.00
  57.30
  52.07
  47.36
  43.13
  39.31
  35.88
  32.79
  30.01
  27.51
  25.26
  23.24
  21.41
  19.77
  18.29
  16.96
  15.77
  14.69
  13.72
  12.85
  12.06
  11.36
  10.72
  10.15
  9.64
  9.17
  8.75
  8.38
  8.04
  7.74
  7.46
Revenue, $m
  3
  8
  12
  18
  25
  35
  48
  63
  82
  105
  132
  162
  197
  236
  279
  327
  378
  434
  493
  556
  624
  694
  769
  847
  928
  1,014
  1,102
  1,195
  1,291
  1,391
  1,494
Variable operating expenses, $m
 
  22
  33
  49
  70
  97
  132
  175
  228
  290
  364
  448
  544
  652
  771
  902
  1,044
  1,197
  1,362
  1,537
  1,722
  1,918
  2,123
  2,339
  2,564
  2,800
  3,045
  3,300
  3,565
  3,841
  4,128
Fixed operating expenses, $m
 
  12
  13
  13
  13
  13
  14
  14
  14
  15
  15
  15
  16
  16
  16
  17
  17
  17
  18
  18
  19
  19
  19
  20
  20
  21
  21
  22
  22
  23
  23
Total operating expenses, $m
  21
  34
  46
  62
  83
  110
  146
  189
  242
  305
  379
  463
  560
  668
  787
  919
  1,061
  1,214
  1,380
  1,555
  1,741
  1,937
  2,142
  2,359
  2,584
  2,821
  3,066
  3,322
  3,587
  3,864
  4,151
Operating income, $m
  -18
  -26
  -34
  -44
  -58
  -75
  -98
  -126
  -160
  -200
  -247
  -301
  -363
  -432
  -508
  -592
  -683
  -781
  -887
  -999
  -1,117
  -1,242
  -1,374
  -1,512
  -1,656
  -1,807
  -1,963
  -2,127
  -2,296
  -2,473
  -2,656
EBITDA, $m
  -18
  -26
  -33
  -43
  -56
  -74
  -95
  -123
  -156
  -195
  -241
  -293
  -353
  -420
  -495
  -576
  -665
  -760
  -863
  -971
  -1,087
  -1,209
  -1,337
  -1,471
  -1,611
  -1,757
  -1,910
  -2,069
  -2,234
  -2,405
  -2,584
Interest expense (income), $m
  0
  0
  1
  1
  2
  4
  5
  7
  10
  13
  17
  21
  27
  32
  39
  46
  54
  63
  72
  82
  92
  103
  115
  128
  141
  154
  168
  183
  199
  215
  231
Earnings before tax, $m
  -18
  -27
  -34
  -45
  -60
  -79
  -103
  -133
  -170
  -213
  -264
  -323
  -389
  -464
  -547
  -638
  -737
  -844
  -958
  -1,080
  -1,209
  -1,346
  -1,489
  -1,640
  -1,797
  -1,961
  -2,132
  -2,310
  -2,495
  -2,688
  -2,888
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -18
  -27
  -34
  -45
  -60
  -79
  -103
  -133
  -170
  -213
  -264
  -323
  -389
  -464
  -547
  -638
  -737
  -844
  -958
  -1,080
  -1,209
  -1,346
  -1,489
  -1,640
  -1,797
  -1,961
  -2,132
  -2,310
  -2,495
  -2,688
  -2,888

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  5
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  8
  11
  17
  26
  37
  51
  70
  92
  120
  153
  192
  236
  287
  344
  406
  475
  550
  631
  718
  810
  908
  1,011
  1,119
  1,233
  1,351
  1,475
  1,605
  1,739
  1,879
  2,024
  2,175
Adjusted assets (=assets-cash), $m
  3
  11
  17
  26
  37
  51
  70
  92
  120
  153
  192
  236
  287
  344
  406
  475
  550
  631
  718
  810
  908
  1,011
  1,119
  1,233
  1,351
  1,475
  1,605
  1,739
  1,879
  2,024
  2,175
Revenue / Adjusted assets
  1.000
  0.727
  0.706
  0.692
  0.676
  0.686
  0.686
  0.685
  0.683
  0.686
  0.688
  0.686
  0.686
  0.686
  0.687
  0.688
  0.687
  0.688
  0.687
  0.686
  0.687
  0.686
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
Average production assets, $m
  0
  4
  6
  9
  12
  17
  23
  31
  40
  51
  64
  79
  96
  115
  136
  159
  184
  211
  240
  270
  303
  337
  374
  412
  451
  493
  536
  581
  627
  676
  726
Working capital, $m
  2
  -1
  -2
  -3
  -4
  -5
  -7
  -10
  -13
  -16
  -20
  -25
  -30
  -36
  -42
  -50
  -57
  -66
  -75
  -85
  -95
  -106
  -117
  -129
  -141
  -154
  -168
  -182
  -196
  -211
  -227
Total debt, $m
  1
  6
  11
  18
  27
  39
  54
  72
  95
  123
  154
  191
  233
  279
  331
  388
  450
  516
  588
  664
  744
  829
  919
  1,012
  1,110
  1,212
  1,319
  1,429
  1,545
  1,664
  1,789
Total liabilities, $m
  7
  9
  14
  21
  30
  42
  57
  76
  99
  126
  158
  195
  236
  283
  335
  392
  453
  520
  591
  667
  748
  833
  922
  1,016
  1,114
  1,216
  1,322
  1,433
  1,548
  1,668
  1,792
Total equity, $m
  1
  2
  3
  5
  6
  9
  12
  16
  21
  27
  34
  42
  50
  60
  72
  84
  97
  111
  126
  143
  160
  178
  197
  217
  238
  260
  282
  306
  331
  356
  383
Total liabilities and equity, $m
  8
  11
  17
  26
  36
  51
  69
  92
  120
  153
  192
  237
  286
  343
  407
  476
  550
  631
  717
  810
  908
  1,011
  1,119
  1,233
  1,352
  1,476
  1,604
  1,739
  1,879
  2,024
  2,175
Debt-to-equity ratio
  1.000
  2.900
  3.510
  3.890
  4.130
  4.280
  4.390
  4.460
  4.510
  4.550
  4.580
  4.600
  4.610
  4.620
  4.630
  4.640
  4.640
  4.650
  4.650
  4.660
  4.660
  4.660
  4.660
  4.670
  4.670
  4.670
  4.670
  4.670
  4.670
  4.670
  4.670
Adjusted equity ratio
  -1.333
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176
  0.176

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -18
  -27
  -34
  -45
  -60
  -79
  -103
  -133
  -170
  -213
  -264
  -323
  -389
  -464
  -547
  -638
  -737
  -844
  -958
  -1,080
  -1,209
  -1,346
  -1,489
  -1,640
  -1,797
  -1,961
  -2,132
  -2,310
  -2,495
  -2,688
  -2,888
Depreciation, amort., depletion, $m
  0
  0
  1
  1
  1
  2
  2
  3
  4
  5
  6
  8
  10
  11
  14
  16
  18
  21
  24
  27
  30
  34
  37
  41
  45
  49
  54
  58
  63
  68
  73
Funds from operations, $m
  -15
  -26
  -34
  -45
  -59
  -77
  -101
  -130
  -166
  -208
  -258
  -315
  -380
  -453
  -533
  -622
  -719
  -823
  -934
  -1,053
  -1,179
  -1,312
  -1,452
  -1,598
  -1,752
  -1,912
  -2,078
  -2,252
  -2,432
  -2,620
  -2,815
Change in working capital, $m
  1
  0
  -1
  -1
  -1
  -2
  -2
  -2
  -3
  -3
  -4
  -5
  -5
  -6
  -7
  -7
  -8
  -8
  -9
  -10
  -10
  -11
  -11
  -12
  -12
  -13
  -13
  -14
  -15
  -15
  -16
Cash from operations, $m
  -16
  -26
  -33
  -44
  -58
  -76
  -99
  -128
  -163
  -205
  -254
  -310
  -374
  -447
  -527
  -615
  -711
  -814
  -925
  -1,044
  -1,169
  -1,301
  -1,441
  -1,587
  -1,739
  -1,899
  -2,065
  -2,238
  -2,418
  -2,605
  -2,799
Maintenance CAPEX, $m
  0
  0
  0
  -1
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -8
  -10
  -11
  -14
  -16
  -18
  -21
  -24
  -27
  -30
  -34
  -37
  -41
  -45
  -49
  -54
  -58
  -63
  -68
New CAPEX, $m
  0
  -1
  -2
  -3
  -4
  -5
  -6
  -8
  -9
  -11
  -13
  -15
  -17
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -34
  -36
  -38
  -40
  -41
  -43
  -45
  -47
  -49
  -50
Cash from investing activities, $m
  0
  -1
  -2
  -4
  -5
  -6
  -8
  -10
  -12
  -15
  -18
  -21
  -25
  -29
  -32
  -37
  -41
  -45
  -50
  -55
  -60
  -64
  -70
  -75
  -81
  -86
  -92
  -99
  -105
  -112
  -118
Free cash flow, $m
  -16
  -27
  -36
  -47
  -62
  -82
  -107
  -138
  -175
  -220
  -272
  -331
  -399
  -475
  -559
  -652
  -752
  -860
  -975
  -1,098
  -1,229
  -1,366
  -1,511
  -1,662
  -1,820
  -1,985
  -2,157
  -2,336
  -2,523
  -2,716
  -2,917
Issuance/(repayment) of debt, $m
  -2
  3
  5
  7
  9
  12
  15
  19
  23
  27
  32
  37
  42
  47
  52
  57
  62
  67
  71
  76
  81
  85
  89
  94
  98
  102
  106
  111
  115
  120
  124
Issuance/(repurchase) of shares, $m
  14
  28
  35
  47
  62
  82
  106
  137
  175
  219
  271
  330
  398
  474
  558
  650
  750
  858
  974
  1,096
  1,227
  1,364
  1,508
  1,660
  1,818
  1,983
  2,155
  2,334
  2,520
  2,713
  2,914
Cash from financing (excl. dividends), $m  
  12
  31
  40
  54
  71
  94
  121
  156
  198
  246
  303
  367
  440
  521
  610
  707
  812
  925
  1,045
  1,172
  1,308
  1,449
  1,597
  1,754
  1,916
  2,085
  2,261
  2,445
  2,635
  2,833
  3,038
Total cash flow (excl. dividends), $m
  -4
  3
  5
  7
  9
  12
  15
  18
  22
  27
  31
  36
  41
  46
  51
  55
  60
  65
  70
  74
  79
  83
  87
  91
  95
  100
  104
  108
  112
  117
  121
Retained Cash Flow (-), $m
  3
  -28
  -35
  -47
  -62
  -82
  -106
  -137
  -175
  -219
  -271
  -330
  -398
  -474
  -558
  -650
  -750
  -858
  -974
  -1,096
  -1,227
  -1,364
  -1,508
  -1,660
  -1,818
  -1,983
  -2,155
  -2,334
  -2,520
  -2,713
  -2,914
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  1
  2
  3
  4
  6
  9
  12
  16
  20
  26
  32
  40
  48
  58
  69
  80
  93
  107
  121
  137
  153
  171
  189
  208
  228
  249
  271
  294
  318
  342
Cash available for distribution, $m
 
  -24
  -31
  -40
  -53
  -70
  -92
  -119
  -152
  -192
  -240
  -295
  -358
  -428
  -508
  -595
  -690
  -793
  -904
  -1,022
  -1,148
  -1,281
  -1,421
  -1,568
  -1,722
  -1,883
  -2,051
  -2,226
  -2,407
  -2,596
  -2,793
Discount rate, %
 
  6.60
  6.93
  7.28
  7.64
  8.02
  8.42
  8.84
  9.29
  9.75
  10.24
  10.75
  11.29
  11.85
  12.45
  13.07
  13.72
  14.41
  15.13
  15.88
  16.68
  17.51
  18.39
  19.31
  20.27
  21.29
  22.35
  23.47
  24.64
  25.87
  27.17
PV of cash for distribution, $m
 
  -23
  -27
  -33
  -40
  -48
  -56
  -66
  -75
  -83
  -90
  -96
  -99
  -100
  -98
  -94
  -88
  -80
  -72
  -62
  -53
  -43
  -35
  -27
  -21
  -15
  -11
  -8
  -5
  -3
  -2
Current shareholders' claim on cash, %
  100
  26.6
  9.7
  3.8
  1.6
  0.7
  0.3
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

FINANCIAL RATIOS  of  Biocept (BIOC)

Valuation Ratios
P/E Ratio -6
Price to Sales 36.3
Price to Book 108.9
Price to Tangible Book
Price to Cash Flow -6.8
Price to Free Cash Flow -6.8
Growth Rates
Sales Growth Rate 200%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 100%
Total Debt to Equity 100%
Interest Coverage 0
Management Effectiveness
Return On Assets -189.5%
Ret/ On Assets - 3 Yr. Avg. -259.5%
Return On Total Capital -600%
Ret/ On T. Cap. - 3 Yr. Avg. -270%
Return On Equity -720%
Return On Equity - 3 Yr. Avg. -434.4%
Asset Turnover 0.3
Profitability Ratios
Gross Margin -133.3%
Gross Margin - 3 Yr. Avg. -177.8%
EBITDA Margin -600%
EBITDA Margin - 3 Yr. Avg. -766.7%
Operating Margin -600%
Oper. Margin - 3 Yr. Avg. -733.3%
Pre-Tax Margin -600%
Pre-Tax Margin - 3 Yr. Avg. -766.7%
Net Profit Margin -600%
Net Profit Margin - 3 Yr. Avg. -766.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

BIOC stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BIOC stock intrinsic value calculation we used $5 million for the last fiscal year's total revenue generated by Biocept. The default revenue input number comes from 2016 income statement of Biocept. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BIOC stock valuation model: a) initial revenue growth rate of 57.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.6%, whose default value for BIOC is calculated based on our internal credit rating of Biocept, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Biocept.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BIOC stock the variable cost ratio is equal to 276.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $12 million in the base year in the intrinsic value calculation for BIOC stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 13.9% for Biocept.

Corporate tax rate of 27% is the nominal tax rate for Biocept. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BIOC stock is equal to 24.6%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BIOC are equal to 48.6%.

Life of production assets of 10 years is the average useful life of capital assets used in Biocept operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BIOC is equal to -15.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1 million for Biocept - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 27 million for Biocept is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Biocept at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
ABT Abbott Laborat 63.32 80.26  buy
A Agilent Techno 63.85 67.60  hold
TROV TrovaGene 0.790 0.05  str.sell
TMO Thermo Fisher 216.85 95.38  str.sell
FMI Foundation Med 136.95 0.22  str.sell
GHDX Genomic Health 57.34 11.72  str.sell
DGX Quest Diagnost 114.46 103.25  hold
ROSG Rosetta Genomi 0.430 0.50  buy

COMPANY NEWS

▶ Why RH, Biocept, and Lowe's Jumped Today   [Jul-13-18 04:49PM  Motley Fool]
▶ BIOC: Whats Going on With Biocept Stock?   [03:46PM  InvestorPlace]
▶ Why Biocept, Inc. Stock Is Plunging Today   [Jul-12-18 12:26PM  Motley Fool]
▶ Biocept Reports First Quarter 2018 Financial Results   [May-15-18 04:05PM  PR Newswire]
▶ Biocept to Present at the 7th Annual MicroCap Conference   [Apr-03-18 08:05AM  PR Newswire]
▶ Biocept, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ Biocept to Present at the 30th Annual ROTH Conference   [Mar-06-18 08:05AM  PR Newswire]
▶ Scientists seek super-shot for flu 100 years after pandemic   [Jan-17-18 01:45PM  Associated Press]
▶ ETFs with exposure to Biocept, Inc. : December 28, 2017   [Dec-28-17 11:52AM  Capital Cube]
▶ ETFs with exposure to Biocept, Inc. : December 11, 2017   [Dec-11-17 01:34PM  Capital Cube]
▶ What Spooked Biocept Inc (BIOC) Investors Today   [Dec-06-17 12:53PM  SmarterAnalyst]
▶ Biocept Inc Shares Skyrocket on Surprise Patent Victory   [Dec-05-17 01:57PM  SmarterAnalyst]
▶ ETFs with exposure to Biocept, Inc. : November 29, 2017   [Nov-29-17 11:12AM  Capital Cube]
▶ ETFs with exposure to Biocept, Inc. : November 13, 2017   [Nov-13-17 11:51AM  Capital Cube]
▶ Biocept Reports Third Quarter 2017 Financial Results   [Nov-09-17 04:05PM  PR Newswire]
▶ Biocept, Inc. to Host Earnings Call   [10:10AM  ACCESSWIRE]
▶ ETFs with exposure to Biocept, Inc. : November 2, 2017   [Nov-02-17 11:53AM  Capital Cube]
▶ ETFs with exposure to Biocept, Inc. : October 23, 2017   [Oct-23-17 10:23AM  Capital Cube]
▶ ETFs with exposure to Biocept, Inc. : October 10, 2017   [Oct-10-17 11:03AM  Capital Cube]
▶ What You Must Know About Biocept Incs (BIOC) Risks   [Oct-04-17 06:46PM  Simply Wall St.]
▶ Biocept Launches Liquid Biopsy Test for NRAS Mutations   [Sep-05-17 08:05AM  PR Newswire]
▶ Biocept Reports Second Quarter 2017 Financial Results   [Aug-10-17 04:05PM  PR Newswire]
▶ ETFs with exposure to Biocept, Inc. : August 3, 2017   [Aug-03-17 07:47PM  Capital Cube]
▶ Global stocks rise on corporate earnings, ahead of Fed   [Jul-26-17 08:10AM  Associated Press]
▶ Novel leukemia treatment could be 1st US gene therapy   [Jul-12-17 06:21PM  Associated Press]
▶ ETFs with exposure to Biocept, Inc. : June 28, 2017   [Jun-28-17 02:35PM  Capital Cube]
▶ Biocept Added to the Russell Microcap Index   [Jun-26-17 08:05AM  PR Newswire]
▶ ETFs with exposure to Biocept, Inc. : June 16, 2017   [Jun-16-17 03:27PM  Capital Cube]
▶ ETFs with exposure to Biocept, Inc. : June 5, 2017   [Jun-05-17 02:03PM  Capital Cube]
▶ Vaccine may cut HPV infections, an oral cancer risk, in men   [May-18-17 10:33AM  Associated Press]
▶ ETFs with exposure to Biocept, Inc. : May 12, 2017   [May-12-17 03:43PM  Capital Cube]
▶ Biocept Reports First Quarter 2017 Financial Results   [May-11-17 04:05PM  PR Newswire]
Financial statements of BIOC
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.